04 Nov SECURE-IBD
Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) is an international, pediatric and adult database to monitor and report on outcomes of COVID-19 occurring in IBD patients.
With the collaboration of our entire IBD community, we will rapidly be able to define the impact of COVID-19 on patients with IBD and how factors such as age, comorbidities, and IBD treatments impact COVID outcomes.
- This is an international effort—we are counting on robust participation and collaboration.
- We will provide the IBD community with regularly updated summary information about reported cases, including numbers of cases by country, number of cases by treatment, etc. so the entire IBD community has access to these data.
- The database contains only de-identified data, in accordance with HIPAA Safe Harbor De-Identification standards.
- The UNC-Chapel Hill Office for Human Research Ethics has determined that storage and analysis of de-identified data does not constitute human subjects research as defined under federal regulations [45 CFR 46.102 and 21 CFR 56.102] and does not require IRB approval.
VARIATION Study: Reduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy
VARIATION is a prospective multi-centre Irish study aiming to determine the impact of IBD and various
Molecular Biomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection study In Crohn's disease patients
STEIG: Stelara Treatment Effectiveness in Irish Gastroenterology
STEIG is a retrospective study of clinical outcomes of off licence treatment with Ustekinumab for